Validating METCAM/MUC18 as a Novel Biomarker to Predict the Malignant Potential of Prostate Cancer at an Early Stage by Using a Modified Gold Nanoparticles-Based Lateral Flow Immunoassay

Jui-Chuang Wu 1,2,*, Yin-Huan Chuang 1, Yu-Chun Wei 1, Chia-Chi Hsieh 1, Yuan-Hung Pong 3,4, Yenn-Rong Su 5, Vincent F.-S. Tsai 3,4 and Guang-Jer Wu 6,7,8*

Abstract: (1) Background: To further validate METCAM/MUC18 as a diagnostic biomarker for prostate cancer, a modified Lateral Flow Immune Assay (LFIA) with increased sensitivity and specificity was designed by taking advantage of the extremely high affinity between biotin and streptavidin and used. (2) Methods: The combination of a commercial biotinylated rabbit antibody (EPP11278), or the home-made biotinylated chicken antibody, and the nano-gold conjugated home-made antibodies; nano-gold conjugated antibodies; streptavidin; malignant potential; prostate cancer keywords: biomarker; biosensor; METCAM/MUC18; human serum; modified LFIA; biotinylated antibodies; nano-gold conjugated antibodies; streptavidin; malignant potential; prostate cancer

1. Introduction

Prostate cancer is the top-leading cause of cancer in males and one of the major causes of cancer death in the world [1]. Nevertheless, majority of prostate cancer is indolent; however, about 1/10 of prostate cancer are aggressive, from which the patients may succumb to death within one year of the first diagnosis [2,3]. The most common diagnosis test for the cancer is to detect an elevated serum prostate-specific antigen (PSA)
level [4]. However, the elevated level of PSA in the serum is not always prognostic of the correct pathologic stage of the cancer or the presence of an indolent or a metastatic disease; thus, it results in at least 20–25% of false diagnosis [4]. Many potential biomarkers for predicting prostate cancer progression have been published [5–8] and some of them are even Gleason grade-specific biomarkers [8]. However, only PSA, Prostate Health Index, and PCA3 have been approved by Food and Drug Administration for the diagnosis of prostate cancer [5]. Therefore, to find a better diagnostic marker for accurate predicting the malignant propensity of prostate cancers is still an urgent need. The new diagnostic marker should at least compensate for, or even better to replace the present serum PSA test. We have previously showed that METCAM/MUC18, an immunoglobulin-like cell adhesion molecule [9], is capable of driving the spread of prostate cancer to multiple organs [9–17]. Furthermore, based on our immunohistochemistry results, METCAM/MUC18 was overly expressed in most (80%) prostate cancer at advanced pathological stages and in all patients (100%) with the premalignant PIN (prostatic intraepithelial neoplasia); however, it was not expressed in most (80%) normal prostates nor in the prostates of all (100%) the benign prostatic hyperplasia (BPH) patients [9–11]; we suggest that it has the high potential to be used as a novel diagnostic biomarker for predicting the metastatic potential of human prostate cancer at an early pre-malignant stage (PIN) [9–11,16], and perhaps for distinguishing the aggressive cancers from indolent ones [15–17].

To test the above hypothesis, we first showed to be able to use three immunological methods, such as the immunoblot (Western blot) analysis, the enzyme-linked immunosorbent assay (ELISA), and membrane-based lateral flow immunoassay (LFIA), to detect the possible presence of the METCAM/MUC18 antigen in human serum specimens [18]. Then, we further demonstrated that the METCAM/MUC18 concentrations were elevated in the serum of the prostate cancer patients, suggesting that the elevated serum METCAM/MUC18 concentrations may be used for predicting the malignant potential of prostate cancer and at least complement the PSA test [18]. However, the first two methods were consisted of many labor-intensive steps, which may create errors in human operators, resulting in irreproducible data. Moreover, the serum concentration of METCAM/MUC18 was directly proportional to that of PSA only when PSA concentrations were less than 7 ng/mL, but not when PSA was between >7 ng/mL and 1219 ng/mL. Though the third method was better than the two methods in sensitivity and also in the aspect of being proportional to PSA, it somewhat also had limited sensitivity. This could be due to the interfering substances in human serum when polyclonal antibodies were used for the assay as pointed out by previously published findings [19].

To overcome these obstacles and to further validate METCAM/MUC18 as a diagnosis marker for the cancer, the purpose of this research was to improve and modify the traditional LFIA test to increase the sensitivity and specificity of the assay by taking advantage of the extremely high affinity between biotin and streptavidin [20]. In brief, in this modified LFIA the biotinylated primary antibodies were first allowed to interact with the antigen and the nano-gold conjugated another primary antibody, which recognized different epitopes, to form ternary complexes. The ternary complexes were then loaded on the conjugate pad in the LFIA assembly and further developed into the nitrocellulose (NC) membrane. The streptavidin was sprayed on the test line of the NC membrane to facilitate capturing the complexes. The secondary goat Abs against the primary chicken or rabbit antibody were sprayed at the control line to capture the excess unbound nano-gold conjugated primary Abs [21–23].

In this report, we used two different combinations of biotinylated chicken or rabbit antibodies and nano-gold-conjugated chicken or rabbit antibodies to hopefully obtain the data with the least standard deviations and with the best statistically significant results. We found that both the combinations of a commercial biotinylated rabbit anti-huMETCAM/MUC18 (EPP11278) and nano-gold-conjugated home-made chicken antibody and that of a biotinylated home-made chicken anti-huMETCAM/MUC18 Ab with a commercial rabbit antibody (MBS2529469 or EPP11278) fulfilled the expectation. Different
concentrations of the recombinant METCAM/MUC18 proteins, NM-GST, and C-terminus-
GST, were used as the positive and the negative controls, respectively. Under optimal
conditions, the signals of the positive control protein, NM-GST, and the negative con-
trol protein, C-terminus-GST, could be clearly differentiated with a significant 5 to 8-fold
difference; thus, a standard calibration curve of human recombinant antigens was estab-
lished. By comparing the signals from various human serum samples to the standard
 calibration curve, the concentrations of METCAM/MUC18 in the serum samples could
be determined. Thus, this modified LFIA method not only had a higher sensitivity and
 specificity to differentiate the positive and negative control proteins, but also was able to
determine the huMETCAM/MUC18 protein concentration in human serum specimens. It
also showed that the serum METCAM/MUC18 concentrations were proportional to most
serum PSA concentrations. The standard deviations of the METCAM/MUC18 concentra-
tions determined by this modified LFIA were significantly smaller and, therefore, better
than the traditional LFIA and the PSA test. Similar to our previous findings, the serum
METCAM/MUC18 concentrations from the prostate cancer patients were significantly
higher than normal individuals, BPH patients, and the treated patients [18,21–23]. The
most significant finding was that the serum METCAM/MUC18 concentrations from the
pre-malignant PIN patients were higher than the prostate cancer patients [21–23]. Based
on the evidence presented in this report, this modified LFIA had a high potential to become
an accurate, simple, and rapid diagnostic test for accurate prediction of the malignant
propensity of clinical prostate cancer at the premalignant stage, which is different from the
PSA test.

2. Materials and Methods

2.1. Materials

Human serum samples were from 8 normal individuals, 4 patients with BPH, 2 with
PIN, 14 with high-grade prostate cancer, and 2 treated patients. Chicken anti-human
METCAM/MUC18 was home-made [9]. Chicken anti-murine METCAM/MUC18 was
also home-made [24]. The rabbit anti-METCAM/MUC18 antibody, which recognized the
N-terminal epitopes aa#26-350 of METCAM/MUC18, with or without biotin-conjugation
was from Elabscience (EPP11278) (Houston, TX, USA) or from MyBiosource (MBS2529469)
(San Diego, CA, USA). Goat anti-rabbit antibody (2 mg/mL) and goat anti-chicken anti-
body (1 mg/mL) were from Jackson lab Inc (Bar Harbor, ME, USA). BSA (Cat #AD0023),
sucrose (Cat # DB0194), and Tween 20 (Cat #TB0560) were from Bio Basic Inc. (Toronto,
Canada). BSA and BSA-FV were also from Promega (Madison, WI, USA). Tween 20 was
also from Promega. Triton X-100 (Cat # DB0198) was from Sigma-Aldrich Co (St. Louis,
MO, USA). Nitrocellulose membrane (Cat # M10-00101), sample pad (Cat # M10-01401),
conjugated pad (Cat # M10-00701), absorbent pad (Cat # M10-01701), and plastic backing
pad (Cat # M10-00400) were from Rega Biotech Co, (Taipei, Taiwan). Pall Vivid 170 nitro-
cellulose membrane (Cat # VIV1702503R) from Pall Co, USA (Port Washington, NY, USA)
(Rainbow Biotech Co., Taipei, Taiwan) also was used for LFIA. Sample pad, conjugate
pad, and plastic backing pad (Cat # ARcare® 9021D) were also from Prisma Biotech Co
(Taipei, Taiwan). Absorption pad (Cellulose Fiber Sample Pads (CFSP203000)) was also
from BERTEC Biotechnology (Torrance, CA, USA). Colloidal gold (40 nm) was from Rega
Biotechnology. Streptavidin (1 mg/mL) was from Rainbow Biotechnology (Taipei, Taiwan).
General chemicals were from Bio Basic (Toronto, ON, Canada).

2.2. Preparation of Recombinant METCAM/MUC18 Proteins

The recombinant METCA/MUC18 proteins were obtained and purified as described [9,24].
The final protein concentration of each recombinant protein was determined by measuring
the A280 in a spectrophotometer or quantitated by a Biuret method (BioRad), verified by
SDS-PAGE and staining. The recombinant proteins were kept frozen at −20 °C till use.
Two recombinant proteins, NM-GST, C-terminus-GST were used for establishing standard
calibration curves.
2.3. Preparation of Human Serum Samples

Human whole bloods were obtained from voluntary donors with the consensus and an approval of Institutional Review Board at Chung Yuan Christian University (protocol code 201706214-A1, 2017–2018, and 20180519-8, 2018–2019). Human blood (15 or 30 mL per person) was withdrawn into one or two 16 mL conical centrifuge tubes without any heparin and processed to serum by centrifugation twice at 180 × g for 20 min in a S4180 swing out rotor in a table top centrifuge as described [18]. The final clear yellowish serum was aliquoted in 0.5 or 1mL portions in several new 1.5 mL Eppendorf centrifuge tubes and stored in −20 °C freezer until use.

2.4. Preparation of Biotinylated Chicken Antibody

The home-made chicken antibody was biotinylated by the using the biotin (Type A) Fast Conjugation Kit from Abcam (ab201795-300ug) [21–23]. The epitope-recognition of the antibody was not affected [Manual for antibody conjugation kit from Abcam]. In brief, 100 µL (1–2.5 mg/mL) of dialyzed chicken antibody was added 10 µL of modifier to form the antibody-modifier mixture. The antibody-modifier mixture was added to the vial of the lyophilized conjugation, after thoroughly mixing the vial was capped, and the reaction was allowed to occur at room temperature (26 °C) for 15 min. After addition of 10 µL quencher, the reaction was allowed to occur for 4 min and added 400 µL of PBS, and dialyzed against PBS with three changes of PBS at 4 °C. The final biotinylated antibody solution was added Na. Azide to 0.02% and stored at 4 °C till use. The final concentration was between 0.34–0.44 mg/mL. The biotinylated chicken antibody was diluted with PBS to about 0.02–0.04 mg/mL before use in LFIA. The avidity and specificity of the biotinylated antibody was verified by using Western blot analyses to test the recognition of their specific epitopes in whole cell lysates, which were prepared from SK-MEL 28, PC-3, DU145, or TSU-PR1 cell lines, and in various recombinant METCAM/MUC18 proteins.

2.5. Western Blot Analysis

The Western blot analysis was done as described [25] with slight modifications [9–12,14,15,18]. In brief, after electrophoresis the gel was electro-blotted to a nitrocellulose membrane in a BioRad mini-blot apparatus, the METCAM/MUC18 band was identified by reacting with 1/300 dilution of our home-made chicken anti-human METCAM/MUC18 recombinant protein internal epitopes aa# 212-374 IgY [9], subsequently with 1/2000 dilution of an AP-conjugated rabbit anti-chicken antibody, and finally with a color reaction as described [9–12,14,15,18]. The METCAM/MUC18 band on the nitrocellulose membrane was imaged by an Epson Perfection V330 Photo scanner and stored as a JPG file and quantified by the Image J software.

2.6. The Modified Lateral Flow Immunoassay (LFIA)

LFIA was carried on a 0.4 cm × 2.5 cm nitrocellulose membrane strip as described [18,21–23] and the set-up of LFIA is illustrated in the following Figure 1.

In brief, the test line (T-line) contained 0.53 µg of streptavidin per 0.4 cm strip. The control line (C-line) contained either 0.53 µg of goat antibody against primary chicken antibody or 1.07 µg of goat antibody against primary rabbit antibody per 0.4 cm strip. Both were printed with an AgitestTM RP-100 printing machine (Rega Biotech Inc., Taiwan) on a 30 × 25 cm nitrocellulose membrane (Cat # M10-00101, Rega Biotech co), which was baked for 30 min, cooled, and kept in a dehumidifier, and cut into about 75 of 0.4 cm × 2.5 cm strips with a computer-operated automatic micro cutter machine (model JS-101, HSHUENN, Taiwan) and used for the assembly of LFIA. The lateral flow buffer contained 1XPBS, 10 mM Tris HCl, pH 7.6, 0.15 M NaCl, 10 mM MgCl2, 1 mM ZnCl2, 0.1% Triton X-100, 0.5% (5 mg/mL) BSA or BSA-FV, and 0.02% Na. Azide. Conjugation of a primary antibody (either chicken or rabbit antibody) to colloidal gold (40 nm particles) was carried out at 0 °C or room temperature for 2 h, centrifuged, washed with cold 10 mM Tris.HCl buffer, pH 7.6, and finally suspended in 0.02 mL of LF buffer before use. The absorption peak of the
gold nanoparticles had a slight shift from 525 nm to 530 nm, indicating that there was no aggregation after the antibody conjugation. Then, 10 µL of antibody (about 0.2 µg of rabbit antibody or 0.5 µg of chicken antibody)-gold nanoparticles (about 7.85 µg) suspension was mixed with the antigen (10 µL) and biotinylated antibody (10 µL of 47 µg/mL of biotinylated rabbit antibody or 20–40 µg/mL of biotinylated chicken antibody) and incubated at room temp for 30 min. After application of the mixture of triple complexes, the LFIA assembly was developed by 3–4 applications of 40–60 µL of LF buffer, disassembled, and only the nitrocellulose membrane strip was allowed to develop color and dried at room temperature. The images in the test line (T-line) and the control line (C-line) were scanned with an Epson Scanner and the intensities of the bands were determined by the Image J version 3.1. Each LFIA analysis of the control proteins was repeated 10 times and that of serum 7 times.

Figure 1. The set-up of modified Lateral Flow Immune Assay (LFIA). LFIA was set up by assembling of the sample pad, the conjugation pad, the nitrocellulose membrane, and the absorption pad on top of a plastic backing card. Streptavidin was printed on the T-line of the nitrocellulose membrane and goat antibody against primary chicken antibody or rabbit antibody printed on the C-line of the nitrocellulose membrane. (A) shows the set-up of modified LFIA by using the first antibody combination (commercial biotinylated rabbit antibody EPP11278 and nano-gold conjugated home-made chicken antibody). (B) shows the set-up of modified LFIA by using the second antibody combination (biotinylated home-made chicken antibody and nano-gold conjugated commercial rabbit antibody EPP11278).
2.7. Statistical Analysis

Standard deviation of each set of data and $R^2$ of two different sets of data were analyzed by the build-in programs in the Excel. The one-way ANOVA method in the SPSS software (IBM SPSS statistics, version 20) was used for statistical analysis among several sets of data. The difference among different sets of data was considered statistically significant if $p$ value was <0.05.

3. Results

3.1. Identification of Antibodies for Modified LFIA

To identify possible the antibodies with the best specificity and sensitivity, Western blot assay method was used to analyze our home-made chicken antibody and two polyclonal rabbit antibodies from commercial sources for their abilities to recognize the full size huMETCAM/MUC18 protein in the whole cell lysates from various prostate cancer cell lines and the respective recombinant proteins that contain different epitopes. The results of the epitope recognition of these antibodies are summarized in Table 1. Our home-made chicken antibody, which recognized the amino acid residues from aa #212-374 had the best specificity and sensitivity for huMETCAM/MUC18, the next best was a commercial rabbit antibody: EPP11278, which recognized the epitopes aa #26-350. These antibodies were used for the modified LFIA, as shown in Figure 1. This report includes the results of the modified LFIA by using the two antibody combinations: (a) a commercial biotinylated rabbit antibody (EPP11278) with a nano-gold-conjugated home-made chicken antibody and (b) the home-made biotinylated chicken antibody with a nano-gold-conjugated commercial rabbit antibody (EPP11278).

Table 1. Epitopes recognized by various antibodies.

| Antibodies                  | Size of METCAM/MUC18 (Recognized in WB) | Location of Epitopes (# Amino Acid) | Recombinant Protein of huMETCAM/MUC18 Recognized in WB | Sources        |
|-----------------------------|-----------------------------------------|------------------------------------|--------------------------------------------------------|---------------|
| Chicken Ab                  | 113–150 kDa                             | 212–374                            | M                                                      | Home-made     |
| Biotinylated chicken Ab     | 113–150 kDa                             | 212–374                            | M                                                      | Home-made     |
| Rabbit Ab (MBS2529469 = EPP11278) | 120 kDa                                 | 26–350                             | N                                                      | MyBiosource and Elabscience |
| Biotinylated rabbit Ab (EPP11278) | 120 kDa                                 | 26–350                             | N                                                      | Elabscience   |

* Recombinant proteins of human METCAM/MUC18: N terminus: aa# 1–212, M portion: aa# 212–374, NM portion: aa# 1–374, C-terminus: aa# 375–646.

3.2. The First Antibody Combination: A Commercial Biotinylated Rabbit Antibody (EPP11278) and the Nano-Gold Conjugated Home-Made Chicken Antibody

3.2.1. The Standard Curve of Recombinant Human METCAM/MUC18 Proteins

Figure 2A shows the results of color image intensities in the test lines of the modified LFIA by using the first antibody combination to determine the intensities versus concentrations of the two recombinant METCAM/MUC18 proteins, NM-GST (the positive control) and C-terminus-GST (the negative control). Figure 2B shows the quantitative results of Figure 2A after being scanned and analyzed by the Image J software. As shown in Figure 2B, the positive control (NM-GST) and the negative control (C-terminus-GST) could be clearly differentiated with a significant 3 to 8-fold difference ($p = 0.005$). After correcting the values of the positive control by subtracting the values of the negative control, a standard calibration curve was deduced and Figure 2C shows the resulting linear relationship of intensities versus concentrations ($R^2 = 0.9809$). The standard calibration curve in Figure 2C was used for deducing the METCAM/MUC18 concentrations in various human serum specimens, as shown below:
3.2. The First Antibody Combination: A Commercial Biotinylated Rabbit Antibody (EPP11278) and the Nano-Gold Conjugated Home-Made Chicken Antibody

3.2.1. The Standard Curve of Recombinant Human METCAM/MUC18 Proteins

Figure 2A shows the results of color image intensities in the test lines of the modified LFIA by using the first antibody combination to determine the intensities versus concentrations of the two recombinant METCAM/MUC18 proteins, NM-GST (the positive control) and C-terminus-GST (the negative control). Figure 2B shows the quantitative results of Figure 2A after being scanned and analyzed by the Image J software. As shown in Figure 2B, the positive control (NM-GST) and the negative control (C-terminus-GST) could be clearly differentiated with a significant 3 to 8-fold difference ($p = 0.005$). After correcting the values of the positive control by subtracting the values of the negative control, a standard calibration curve was deduced and Figure 2C shows the resulting linear relationship of intensities versus concentrations ($R^2 = 0.9809$). The standard calibration curve in Figure 2C was used for deducing the METCAM/MUC18 concentrations in various human serum specimens, as shown below:

![Figure 2A: Recombinant std protein image combo1](image1)

![Figure 2B: Positive and negative controls combo1](image2)

![Figure 2C: Calibration curve combo 1](image3)

Figure 2. (A) Recombinant std protein image combo1, (B) Positive and negative controls combo1, (C) Calibration curve combo 1. Establish the calibration curve from recombinant huMETCAM/MUC18 proteins as determined by a modified LFIA method using the combination of biotinylated rabbit antibody (EPP11278) and nanogold-conjugated home-made chicken antibody. (A) shows the intensities of the two recombinant METCAM/MUC18 proteins, the positive control protein, NM-GST (N-terminus and the middle portions fused to GST), and the negative control protein, C-terminus-GST (the C-terminus portion fused to GST), at different concentrations. C stands for control lines and T for test lines. (B) shows the quantitative results of the intensities of the two recombinant METCAM/MUC18 proteins at different concentrations. (C) shows the standard calibration curve obtained by subtracting the intensity of the negative control protein from the positive control protein.

3.2.2. The Serum METCAM/MUC18 Concentrations in Various Human Serum Samples

Figure 3A shows the color images in the test lines of 28 serum samples from normal individuals, BPH patients, premalignant prostate cancer patients, prostate cancer patients with different Gleason score, and the treated prostate cancer patients. Table 2 shows the characteristics of 30 patients and the pathological grades of 14 prostate cancer patients. Figure 3B shows that the quantitative results after analyzing the image intensity with the Image J software. As shown in Figure 3B,C, the average concentrations of METCAM/MUC18 in human serum from the pre-malignant PIN patients and the prostate cancer patients at various Gleason scores were statistically significantly higher than normal...
Figure 3. (A) Serum image for Combo1, (B) METCAM in patients Combo1, (C) METCAM in patients with Gleason score combo1. HuMETCAM/MUC18 concentrations in various human serum samples were determined by a modified LFIA method using the combination of biotinylated rabbit antibody (EPP11278) and nanogold-conjugated chicken antibody and its relation to the status of patients. (A) shows the intensities of various human serum samples on the test lines (T). The top numbers show the prostate-specific antigen (PSA) score for each patient. (B) shows the average METCAM/MUC18 concentrations with standard deviations in the serum samples from the treated prostate cancer patients, prostate cancer patients with different Gleason score, and patients with prostate premalignant PIN, or BPH, compared to those from normal individuals. The number on top of each bar was the $p$ value when the data were compared to the normal after statistical analysis, as described in “Materials and Methods.” (C) shows the average METCAM/MUC18 concentrations with standard deviations in the serum samples from the treated prostate cancer patients, prostate cancer patients with different Gleason score, and patients with prostate premalignant PIN, or BPH, compared to those from normal individuals. The number on top of each bar was the $p$ value when the data were compared to the normal after statistical analysis, as described in “Materials and Methods”.

Figure 2. (A) Recombinant std protein image combo1, (B) Positive and negative controls combo1, (C) Calibration curve combo 1. Establish the calibration curve from recombinant METCAM/MUC18 proteins as determined by a modified LFIA method using the combination of biotinylated rabbit antibody (EPP11278) and nanogold-conjugated home-made chicken antibody and its relation to the status of patients. Figure 3A shows the color images in the test lines of 28 serum samples from normal individuals, BPH patients, and the treated patients. Figure 3B also shows that the average serum METCAM/MUC18 concentration from the pre-malignant PIN patients was the highest, about seven times higher than the normal individuals and 2.33 times higher than the prostate cancer patients. Figure 3C also shows that the serum METCAM/MUC18 concentrations appeared to linearly increase with increasing Gleason scores.
### Table 2. Patient (male) Characteristics (N = 30).

| Characteristics                          | Age Range (Years) | Age Median (Years) | No of Cases | Percentage (%) |
|------------------------------------------|-------------------|--------------------|-------------|----------------|
| Normal                                   | 28–75             | 52                 | 8           | 27             |
| BPH                                      | 68–75             | 72                 | 4           | 13.3           |
| PIN                                      | 63–87             | 75                 | 2           | 6.7            |
| Prostate carcinoma (total)               | 50–93             | 72                 | 14          | 47             |
| Radiotherapy                             | 67–73             | 70                 | 2           | 6.7            |
| Pathological grades of Prostate carcinoma|                   |                    |             |                |
| Gleason score 3 + 3                      | 93                | 93                 | 1           | 3.3            |
| Gleason score 3 + 4 or 4 + 3             | 63–85             | 74                 | 6           | 20             |
| Gleason score 4 + 4                      | 50–75             | 63                 | 4           | 13.3           |
| Gleason score 4 + 5 or 5 + 4             | 69–86             | 78                 | 2           | 6.7            |
| Gleason score 5 + 5                      | 83                | 83                 | 1           | 3.3            |

3.2.3. The Relation of Serum MECTAM/MUC18 Concentrations with PSA

Figure 4A shows that the serum METCAM/MUC18 concentrations determined by this modified LFIA were linearly proportional to most of the serum PSA concentrations ($R^2 = 0.8244$), when PSA was less than 12 ng/mL. Figure 4B–D show that they were somewhat exponentially proportional to most PSA, when PSA was less than 60 ng/mL ($R^2 = 0.3754$), less than 350 ng/mL ($R^2 = 0.4681$), and less than 1219 ng/mL ($R^2 = 0.4027$), respectively.

(A) METCAM/MUC18 Vs PSA

(B) METCAM/MUC18 Vs PSA

Figure 4. Cont.
Figure 4. (A) METCAM vs. PSA (#1) combo1, (B) METCAM vs. PSA (#2) combo1, (C) METCAM vs. PSA (#3) combo1, (D) METCAM vs. PSA (#4) combo1. Relation of PSA to the huMETCAM/MUC18 concentrations determined by the modified LFIA method by using the combination of biotinylated rabbit antibody and nanogold-conjugated chicken antibody. The concentration of serum METCAM/MUC18 was compared to PSA in each person. (A) shows the results of serum METCAM/MUC18 concentrations versus PSA when PSA was less than 12 ng/mL, (B–D) show the results of serum METCAM/MUC18 concentrations versus PSA when PSA were less than 60 ng/mL, less than 350 ng/mL, and less than 1219 ng/mL, respectively.

3.3. The Second Antibody Combination: The Home-Made Biotinylated Chicken Antibody and a Nano-Gold Conjugated Commercial Rabbit Antibody (EPP11278 or MBS2529469)

3.3.1. The Standard Curve of Recombinant Human METCAM/MUC18 Proteins

Figure 5A shows the results of the color image intensities in the test lines of the modified LFIA by using the second antibody combination to determine the intensity versus concentrations of the two recombinant METCAM/MUC18 proteins, NM-GST (the positive control) and C-terminus-GST (the negative control). Figure 5B shows the quantitative results of the Figure 5A after being scanned and analyzed by the Image J software. As shown in Figure 5B, the positive control protein (NM-GST) and the negative control protein (C-terminus-GST) could be clearly differentiated with a significant 2 to 7-fold difference (P = 0.011). After correcting the values of the positive control by subtracting the values of the negative control, a standard calibration curve was deduced and Figure 5C shows the resulting linear relationship of intensities versus concentrations (R² = 0.9394).
standard calibration curve in Figure 5C was used for deducing the METCAM/MUC18 concentrations in various human serum specimens, as shown below:

![Standard Calibration Curve](image)

**Figure 5.** (A) Recombinant std protein image combo2, (B) Positive and negative controls combo2, (C) Calibration curve combo2. Establish the calibration curve from recombinant METCAM/MUC18 proteins as determined by a modified LFIA method by using home-made biotinylated chicken antibody and nanogold-conjugated rabbit antibody (EPP11278). (A) shows the intensities of the recombinant METCAM/MUC18 proteins, the positive control protein, NM-GST, and the negative control protein, C-terminus-GST, at different concentrations. C stands for control lines and T for test lines. (B) shows quantitative results of the intensities of the two recombinant METCAM/MUC18 proteins at different concentrations. (C) shows the standard calibration curve obtained by subtracting the intensity of the negative control protein from the positive control protein.

### 3.3.2. The Serum METCAM/MUC18 Concentrations in Various Human Serum Samples

Figure 6A shows the color images in the test lines of 28 serum samples from normal individuals, BPH patients, premalignant prostate cancer patients, prostate cancer patients with different Gleason score, and the treated prostate cancer patients. Figure 6B shows that the quantitative results after the images were scanned and their intensities analyzed...
with the Image J software. As shown in Figure 6B,C, the average concentrations of METCAM/MUC18 in human serum from the pre-malignant PIN patients and the prostate cancer patients at various Gleason scores were statistically significantly higher than normal individuals, BPH patients, and the treated patients. Figure 6B also shows that the average serum METCAM/MUC18 concentration from the pre-malignant PIN patients was the highest, about 11 times higher than the normal individuals and 2.2 times higher than the prostate cancer patients. Figure 6C shows that the serum METCAM/MUC18 concentrations somewhat increased with increasing Gleason scores.

![Image](image_url)

**Figure 6.** (A) Serum image for Combo2, (B) METCAM in patients Combo2. HuMETCAM/MUC18, (C) METCAM in patients with Gleason score combo2. HuMETCAM/MUC18 concentrations in various human serum samples were determined by a modified LFIA method using the combination of biotinylated chicken antibody and nanogold-conjugated rabbit antibody (EPP11278) and its relation to the status of patients. (A) shows the intensities of various human serum samples on the test lines (T). (B) shows the average METCAM/MUC18 concentrations with standard deviations in the serum samples from the treated prostate cancer patients, prostate cancer patients, patients with prostate premalignant PIN, or BPH, were compared to those from normal individuals. The number on top of each bar was the p value when the data were compared to the normal after statistical analysis, as described in “Materials and Methods.” (C) shows the average METCAM/MUC18 concentrations with standard deviations in the serum samples from the treated prostate cancer patients, prostate cancer patients with different Gleason score, and patients with prostate premalignant PIN, or BPH, compared to those from normal individuals. The number on top of each bar was the p value when the data were compared to the normal after statistical analysis, as described in “Materials and Methods.”
3.3.3. The Relation of Serum MECTAM/MUC18 Concentrations with PSA

Figure 7A shows that the serum MECTAM/MUC18 concentrations determined by this modified LFIA were linearly proportional to most of the serum PSA concentrations ($R^2 = 0.7995$), when PSA was less than 12 ng/mL. Figure 7B–D show that they were exponentially proportional to most PSA, when PSA was less than 60 ng/mL ($R^2 = 0.4723$), less than 350 ng/mL ($R^2 = 0.5581$), and less than 1219 ng/mL ($R^2 = 0.4624$), respectively.

Figure 7. Cont.
3.4. The Relation of Serum PSA Concentration in Various Patients

Figure 8A shows that the serum PSA concentrations in prostate cancer patients were statistically significantly higher than those in BPH patients, normal individuals, and treated patients, but not higher than those in PIN patients. However, the serum PSA concentrations in PIN patients were not statistically higher than those in BPH patients, normal individuals, and treated patients. The serum PSA concentrations in BPH patients, as anticipated, were statistically higher than normal individuals and treated patients. Figure 8B shows that the serum PSA concentrations did not statistically significantly increased with increasing Gleason scores.
cancer, the patients with premalignant PIN, or the patients with BPH in comparison to those from normal individuals. (A) shows the average PSA concentrations with standard deviations in the serum samples from the treated prostate cancer patients, the patients with prostate cancer, the patients with premalignant PIN, or the patients with BPH in comparison to those from normal individuals. (B) shows that the average PSA concentrations with standard deviations in the serum samples from the treated prostate cancer patients, prostate cancer patients with different Gleason score, and patients with prostate premalignant PIN, or BPH, compared to those from normal individuals. The number on top of each bar was the p value when the data were compared to the normal after statistical analysis, as described in “Materials and Methods”.

4. Discussion

In this report, we presented evidence to show in this modified LFIA that it was possible to improve the traditional LFIA by taking advantage of an extremely high affinity between biotin and streptavidin. Using this modified LFIA with two combinations of biotinylated primary antibodies and nano-gold conjugated antibodies, we were able to establish standard calibration curves from huMETCAM/MUC18 recombinant proteins and used these curves to determine the serum METCAM/MUC18 concentrations in normal individuals, BPH patients, patients with PIN, prostate cancer patients with various Gleason scores, and treated prostate cancer patients. Both antibody combinations showed that the serum METCAM/MUC18 concentrations in the PIN patients and prostate cancer patients were consistently higher than the normal individuals, BPH patients, and the treated prostate cancer patients. It should be noted that the visible intensities of the METCAM/MUC18 band in the serum samples by using the second antibody combination (biotinylated chicken antibody and nano-gold conjugated rabbit antibody) were stronger than those by using the first antibody combination (biotinylated rabbit antibody and nano-gold conjugated chicken antibody), which appeared to be consistent with the better specificity and sensitivity of the home-made chicken antibody for huMETCAM/MUC18 than the commercial rabbit antibody (EPP11278). It was intriguing that the serum METCAM/MUC18 concentrations appeared to increase with increasing Gleason scores, suggesting that serum METCAM/MUC18 concentrations increased with increasing pathological stages and perhaps with the increasing degree of malignancy of the cancer. Surprisingly, the serum METCAM/MUC18 concentrations in the PIN patients were consistently higher than the prostate cancer patients, which could not be achieved by our previous traditional LFIA and ELISA test [18] and also the current PSA test (Figure 8). We also showed that the serum METCAM/MUC18 concentrations were proportional to most of the PSA concentrations. Taken together, we have successfully developed a reliable, cost-effective test to prove not only the use of METCAM/MUC18 as a diagnostic biomarker for predicting the malignant potential of prostate cancer, but also better than a traditional LFIA and the PSA tests in that the elevated serum METCAM/MUC18 can be used to predict the malignant propensity.
of prostate cancer at the premalignant (PIN) stage before becoming a frank malignant cancer (namely a metastatic cancer), which cannot be achieved by the PSA test (Figure 8), suggesting that METCAM/MUC18 has the advantage over the PSA test in early detection of the malignant potential of prostate cancer.

The major advantages of this modified LFIA are that the procedures are relatively simple, user friendly and easy operation by minimal training, high reproducibility, rapid visual results, cost-effective, and easily quantified if equipped with an inexpensive portable, hand-carry detector. The major disadvantage of using LFIA was indicated by previous workers that only qualitative, and at best semi-quantitative results were obtained; nevertheless, we have repetitively proven in our hand that this modified LFIA can be reproducibly used for obtaining quantitative results. Other major disadvantage of using traditional LFIA was that results were variable among different batches of materials and limited by different antibodies used. This has been overcome in our modified LFIA that we have an ample supply of our home-made chicken antibody [9,24] and different alternatives of commercial rabbit antibodies [17,18,21–23]. To ensure continuous supply of antibodies, we are currently investing in the development of monoclonal antibodies in the near future.

The potential limitation for using the METCAM/MUC18 as a diagnostic biomarker for predicting malignant potential of prostate cancer is that it is not prostate organ-specific, since it is also overly expressed in other cancers, such as angiosarcoma, breast cancer, gastric cancer, hepatocellular carcinoma, lung cancers, most melanoma, nasopharyngeal carcinoma type III, osteosarcomas, and pancreatic cancer; however, it is under expressed in some cancers, such as colorectal cancer, nasopharyngeal carcinoma type I, and ovarian cancer [17,26]. Nevertheless, it may be feasible to use the METCAM/MUC18 to at least complement the current biomarker PSA and furthermore, to combine it with other prostate cancer biomarkers for accurately predicting the malignant potential of prostate cancer [4–8,18].

The success of this assay has fulfilled the main purpose of this manuscript that is to have a strong proof of principle in using METCAM/MUC18 as a novel biomarker for predicting the prostate cancer at the early premalignant stage. Furthermore, it has encouraged us and investigators from other groups to have confidence in further validating this bio-marker for predicting the malignant potential of prostate cancer at the early premalignant PIN stage. We will continue expanding our survey cohort in Taiwanese males to further validating the use of METCAM/MUC18 as an alternative biomarker for the early diagnosis of prostate cancer. We will also use this method to explore the possibility of detecting the presence of METCAM/MUC18 antigen in urine samples [27]. If this turns out to be successful, it may be used to replace the current invasive method to obtain clinical specimens for an effective diagnosis of prostate cancer.

5. Conclusions

The rule of thumb for treating prostate cancer or any other cancers is that early detection of any cancer is always better. Because then the treatment can be performed at early stage when the cancer cells still are confined in the organ and less likely to metastasize outside of the organ and therefore, the curative rate is always very high, which is supported by numerous clinical evidences that prostate cancer at an early stage is entirely curable, but not the cancer at late stage. To meet the above purpose, first, this modified LFIA had been greatly improved from the traditional LFIA to become an accurate, simple, and rapid diagnostic method for comparing the concentrations of the human METCAM/MUC18 antigens in sera from normal human individuals with those from prostate cancer patients. Second, this simplified diagnostic assay can be used for accurate diagnosis of the malignant potential of prostate cancer at the pre-malignant (PIN) stage before becoming a frank malignant cancer (namely a metastatic cancer), which is different from the PSA test, suggesting that METCAM/MUC18 appears to have the advantage over the PSA test in early detection of the malignant potential of prostate cancer. Considering the ability of METCAM/MUC18 as a driver for the malignant progression of the cancer, after extensive
follow-up checking of our patients in future, we also believe that METCAM/MUC18 has the high potential to be used for differentiating the indolent prostate cancers from aggressive ones in clinics.

**Author Contributions:** Conceptualization, J.-C.W. and G.-J.W.; methodology, Y.-H.C., Y.-C.W., and C.-C.H.; software, Y.-H.C., Y.-C.W., and C.-C.H.; validation, Y.-H.P., Y.-R.S., and V.F.-S.T.; formal analysis, Y.-H.C., Y.-C.W., and C.-C.H.; investigation, Y.-H.C., Y.-C.W., and C.-C.H.; resources, Y.-H.P., Y.-R.S., and V.F.-S.T.; data curation, Y.-H.C., Y.-C.W., and C.-C.H.; writing—original draft preparation, Y.-H.C., Y.-C.W., and C.-C.H.; writing—review and editing, J.-C.W. and G.-J.W.; visualization, Y.-H.C., Y.-C.W., and C.-C.H.; supervision, J.-C.W. and G.-J.W.; project administration, J.-C.W. and G.-J.W.; funding acquisition, J.-C.W. and G.-J.W. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was supported by NSC (NSC-101-2320-B-033-003), Center for Biomedical Technology at CYCU, Research Center for Circular Economy at CYCU, and the joined project of CYCU and Ten Chan General Hospital, Taiwan.

**Institutional Review Board Statement:** The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board of Chung Yuan Christian University (protocol code 201706214-A1, 2017–2018, and 20180519-8, 2018–2019).

**Informed Consent Statement:** Informed consent was obtained from all human subjects involved in the study.

**Data Availability Statement:** All the data utilized in this study are available upon request to the corresponding author.

**Acknowledgments:** We thank the supports from NSC (Taiwan), Center for Biomedical Technology at CYCU, Research Center for Circular Economy at CYCU, and the joined project of CYCU and Ten Chan General Hospital, Taiwan.

**Conflicts of Interest:** The authors declare no conflict of interests.

**Abbreviations**
Ab: antibody; BPH: benign prostatic hyperplasia; CAM: cell adhesion molecules; LFIA: lateral flow immunoassay; METCAM: metastasis regulating CAM; NC: nitrocellulose; PIN: prostatic intraepithelial neoplasia; PSA: prostate-specific antigen; WB: Western blot.

**References**
1. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer Statistics 2020. *CA Cancer J. Clin.* 2020, 70, 7–30. [CrossRef] [PubMed]
2. Wood, D.P., Jr.; Banks, E.R.; Humphreys, S.; McRoberts, J.W.; Rangneker, V.M. Identification of bone marrow micro-metastases in patients with prostate cancer. *Cancer* 1994, 74, 2533–2540. [CrossRef]
3. Catalona, W.J.; Scott, W.W. Carcinoma of the prostate: A review. *J. Urol.* 1978, 119, 1–8. [CrossRef]
4. Liu, J.; Liu, Y.; Yang, D.; Yang, C.; Mao, L. Current state of biomarkers for the diagnosis and assessment of treatment efficacy of prostate cancer. *Discov. Med.* 2019, 27, 235–243. [PubMed]
5. Murphy, L.; Watson, R.W. Patented prostate cancer biomarkers. *Nat. Rev. Urol.* 2012, 9, 464–472. [CrossRef] [PubMed]
6. Alkhateeb, A.; Rezaeian, I.; Singireddy, S.; Cavallo-Medved, D.; Porter, L.A.; Rueda, L. Transcriptomics signature from next-generation sequencing data reveal new transcriptomic biomarkers related to prostate cancer. *Diagnostics* 2019, 9, 219. [CrossRef] [PubMed]
7. Koharr, I.; Petrovics, G.; Srivastava, S. A rich array of prostate cancer molecular biomarkers: Opportunities and challenges. *Int. J. Mol. Sci.* 2019, 20, 1813. [CrossRef] [PubMed]
8. Hamzeh, O.; Alkhateeb, A.; Zheng, J.Z.; Kandalam, S.; Leung, C.; Atikukke, G.; Cavallo-Medved, D.; Palanisamy, N.; Rueda, L. A hierarchical machine learning model to discover Gleason grade-specific biomarkers related to prostate cancer. *Diagnostics* 2019, 9, 219. [CrossRef] [PubMed]
9. Wu, G.J.; Wu, M.W.H.; Wang, S.W.; Liu, Z.; Peng, Q.; Qu, P.; Yang, H.; Petros, J.A.; Lim, S.D.; Amin, M.B.; et al. Isolation and characterization of the major form of human MUC18 cDNA gene and correlation of MUC18 over-expression in prostate cancer cells and tissues with malignant progression. *Gene* 2001, 279, 17–31. [CrossRef]
10. Wu, G.J.; Varma, V.A.; Wu, M.W.H.; Yang, H.; Wang, S.W.C.; Liu, Z.; Qu, P.; Petros, J.A.; Lim, S.D.; Amin, M.B. Expression of a human cell adhesion molecule, MUC18, in prostate cancer cell lines and tissues. *Prostate* 2001, 48, 305–315. [CrossRef] [PubMed]
11. Wu, G.J. Chapter 7: The role of MUC18 in prostate carcinoma. In Immunohistochemistry and in Situ Hybridization of Human Carcinomas. Volume 2. Molecular Pathology of Lung Carcinoma, Breast Carcinoma, and Prostate Carcinoma; Hayat, M.A., Ed.; Elsevier Sciences/Academic Press: New York, NY, USA, 2004; pp. 347–358.

12. Wu, G.J.; Peng, Q.; Fu, P.; Wang, S.W.C.; Chiang, C.F.; Dillehay, D.L.; Wu, M.W.H. Ectopic expression of human MUC18 increases metastasis of human prostate cancer cells. Gene 2004, 327, 201–213. [CrossRef]

13. Wu, G.J. METCAM/MUC18 and cancer metastasis. Curr. Genom. 2005, 6, 333–349. [CrossRef]

14. Wu, G.J.; Fu, P.; Chiang, C.F.; Hess, W.J.; Greenberg, N.M.; Wu, M.W.H. Increased expression of MUC18 correlates with the metastatic progression of mouse prostate adenocarcinoma in the TRAMP model. J. Urol. 2005, 173, 1778–1783. [CrossRef]

15. Wu, G.J.; Wu, M.W.H.; Liu, Y. Enforced expression of human METCAM/MUC18 increases the tumorigenesis of human prostate cancer cells in nude mice. J. Urol. 2011, 185, 1504–1512. [CrossRef]

16. Wu, G.J. Human METCAM/MUC18 as a Novel Biomarker to Drive and its Specific SiRNAs to Block the Malignant Progression of Prostate Cancer. J. Cell Sci. Ther. 2015, 6, 5. [CrossRef]

17. Wu, G.J. Chapter 1. METCAM/MUC18 promotes tumor progression and metastasis in most human cancers. In Tumor Progression and Metastasis; Lasfar, A., Ed.; InTech-Open Access Publisher: London, UK, 2020; ISBN 978-1-78985-350-6.

18. Pong, Y.H.; Su, Y.R.; Lo, H.W.; Ho, C.K.; Chu, C.T.; Chen-Yang, Y.W.; Tsai, V.F.S.; Wu, J.C.; Wu, G.J. METCAM/MUC18 is a new early diagnostic biomarker for the malignant potential of prostate cancer: Validation with Western blot method, enzyme-linked immunosorbent assay and lateral flow immunoassay. Cancer Biomark. 2020, 27, 377–387. [CrossRef] [PubMed]

19. Bahadır, E.B.; Sezgintürk, M.K. Lateral flow assays: Principles, designs and labels. Trends Anal. Chem. 2016, 82, 286–306. [CrossRef]

20. Wei, Y.C. Comparing Magnetic Beads-Enriched Array Display Immunoassay with the two Gold Nanoparticles-Based Lateral Flow Immunoassay for Determination of the Prostate Cancer Biomarker-METCAM/MUC18 Concentration in Human Serum. Master’s Thesis, Chung Yuan Christian University, Taoyuan, Taiwan, 2018.

21. Chuang, Y.H. Using Magnetic Beads-Enriched Array Display Immunoassay and the Gold Nanoparticles-Based Lateral Flow Immunoassay for Determination of the Prostate Cancer Biomarker-METCAM/MUC18 Concentration in Human Serum. Master’s Thesis, Chung Yuan Christian University, Taoyuan, Taiwan, 2019.

22. Yang, H.; Wang, S.W.C.; Liu, Z.; Wu, M.W.H.; Armstrong, C.; Wu, G.J. Isolation and characterization of murine MUC18 cDNA gene, and correlation of MUC18 expression in murine melanoma cell lines with metastatic ability. Gene 2001, 265, 133–145. [CrossRef]

23. Ausubel, F.M.; Brent, R.; Kingston, R.E.; Moore, D.D.; Seidman, J.G.; Smith, J.A.; Struhl, K. (Eds.) In situ hybridization and immunohistochemistry. In Current Protocols in Molecular Biology; Section 14; Green Publishing Associates and Wiley-Interscience Press: New York, NY, USA, 1987.

24. Wu, G.J. Chapter 2: METCAM/MUC18: A Novel Tumor Suppressor for Some Cancers. In Genes and Cancer; Guy-Joseph, L., Ed.; InTech-Open Access Publisher: London, UK, 2019; ISBN 978-1-78984-427-6.

25. Eskra, J.N.; Rabizadeh, D.; Pavlovich, C.P.; Catalona, W.J.; Luo, J. Approaches to urinary detection of prostate cancer. Prostate Cancer Prostatic Dis. 2019, 22, 362–381. [CrossRef] [PubMed]